Abstract: Within the immune system there is an exquisite ability to discriminate between "self" and "non-self" that is orchestrated by antigen-specific T lymphocytes. Genomic plasticity enables differentiation of naive CD4+ T lymphocytes into either regulatory cells (Treg) that express the transcription factor Foxp3 and actively prevent autoimmune self-destruction or effector cells (Teff) that attack and destroy their cognate target. An example of such plasticity is our recent discovery that leukemia inhibitory factor (LIF) supports Treg maturation in contrast to IL-6, which drives development of the pathogenic Th17 effector phenotype. This has revealed a LIF/IL6 axis in T cell development which can be exploited for modulation using targeted cytokine delivery. Here we demonstrate that LIF-loaded nanoparticles (NPs) directed to CD4+ T cells (i) oppose IL6-driven Th17 development; (ii) prolong survival of vascularized heart grafts in mice; and (iii) expand FOXP3+ CD4+ T cell numbers in a non-human primate model in vitro. In contrast, IL-6 loaded nanoparticles directed to CD4+ T cells increase Th17 development. Notably, nanoparticle-mediated delivery was demonstrated to be critical: unloaded nanoparticles and soluble LIF or IL-6 controls failed to recapitulate the efficacy of cytokine-loaded nanoparticles in induction and/or expansion of Foxp3+ cells or Th17 cells. Thus, this targeted nanoparticle approach is able to harness endogenous immuneregulatory pathways, providing a powerful new method to modulating T cell developmental plasticity in immune-mediated disease indications.
Introduction
In immune competent individuals, antigen-specific CD4+ T lymphocytes play a critical role in immune discrimination between "self" and "non-self", permitting self-tolerance to coexist with immunity against foreign pathogens. Within the family of CD4+ T cells, a subset of CD4+Foxp3+ T cells known as "regulatory" T cells (Treg) maintain peripheral self-tolerance; Foxp3 is the critical transcription factor required for Treg lineage development. It is now recognized that Tregs provide a potential resource for antigen-specific tolerogenic therapy for treatment of autoimmune diseases as well as acceptance of organ or tissue allografts, including bone marrow and stem cell grafts in regenerative medicine.
1,2
In the periphery, naive CD4+ T lymphocytes are quiescent until cognate antigen is recognized, resulting in activation through the antigen-specific T-cell receptor (TCR). The outcome of this activation is regulated by the microenvironment, which includes the strength of signaling through the TCR, concurrent costimulatory or inhibitory signals, and the composition of the cytokine milieu. The cytokine milieu specifically is critical for orchestration of lineage development toward aggressive effector T cell (Teff) or tolerant Treg phenotypes.
3 Interleukin-6 (IL-6) is a potent inflammatory cytokine, and IL-6 target genes in T cells include RORγt, the Th17 lineage-specific transcription factor. Inappropriate Th17 cell activity may cause pathogenic inflammatory disease, including rheumatoid arthritis and inflammatory bowel disease. 4 IL-6 belongs to the IL-6 family of structurally related cytokines where activity is qualified by their receptors, these having a common gp130 subunit combined with specific subunits that define cytokine reactivity.
5 Leukemia inhibitory factor (LIF) is also a member of the IL-6 family, with a similar crystal structure ( Figure 1A ), but, in marked contrast to IL-6, LIF is associated with Tregs and immune tolerance. 6 Given the profound consequences of the effects of IL-6-related cytokines on T cell lineage differentiation, mechanistic studies sought to identify any direct relationship between LIF and IL-6 signaling in T cells. A counterregulatory LIF/IL-6 axis was discovered, where this LIF/ IL-6 axis is directly linked to the Treg (Foxp3 and LIF) and Th17 (RORγt and IL-6) T cell lineage specification. 7 The therapeutic implications of the LIF/IL6 axis may, thus, enable antigen-specific guidance of immune tolerance in vivo via LIF.
Cytokine-based therapeutics are generally limited by short cytokine half-lives and serum protease-mediated degradation, 8 these being natural mechanisms that normally attenuate the powerful effects of cytokines. However, the therapeutic effect of IL-2 has been greatly improved by prolonging its half-life by the attachment of fusion molecules such as polyethylene glycol (PEG) 9 or humanized antibody fragments. 10 We therefore considered that it may be possible to manipulate LIF for therapy, and here our choice was to use biodegradable nanoparticles (NPs) since NPs offer multiple advantages as drug delivery vehicles for cytokine-related therapies, including protection from rapid degradation; prolonged delivery through sustained release; and targeting to specific cell types. 11 The polymer poly(lactide-co-glycolide) (PLGA) is already approved by the FDA for drug delivery applications due to its safety, excellent biocompatibility, and "tunable" release rates. In NP form, PLGA decorated with functional avidin groups on the nanoparticle surface enables modification of the surface through the robust attachment of biotinylated ligands such as PEG, 12 T cellstimulating antibodies, 13 and T cell-targeting antibodies 14 ( Figure 1B ). This technology is well-suited toward stimulation and manipulation of immune cell development through (i) the presence of T cell-specific cell surface molecules that can be targeted by antibody; (ii) on the NP, presentation of multiple targeting ligands per nanoparticle ensuring high valency and avidity of contact with targeted cellular ligands; and (iii) delivery of multiple cytokine molecules per biorecognition event to ensure relatively high concentration of cytokine precisely within the microenvironment of the targeted cell, while avoiding systemic exposure to the therapeutic cytokine.
In this investigation we have confirmed not only that the LIF/IL6 axis can be recapitulated in T cells treated with LIF-NP/IL6-NP but also that the nanoparticulate therapeutic approach is underpinned by controlled, sustained release of bioactive LIF or IL-6 in low, physiological doses within the precise microenvironment of the target cell.
Experimental Section
Nanoparticle Formulation and Characterization. Human LIF (Santa Cruz Cat. No. SC-4377), mouse LIF (Santa Cruz Cat. No. SC-4378), or recombinant mouse IL-6 (eBioscience Cat. No. 14-8061-80) was encapsulated in avidin-coated PLGA nanoparticles using a modified water/ oil/water double emulsion technique. Briefly, 50 µg of cytokine was dissolved in 200 µL of PBS and added dropwise with vortexing to 100 mg of PGLA (50/50 monomer ratio, Durect Corp. Cat. No. B0610-2) in 2 mL of dichloromethane. The resulting emulsion was added to 4 mL of aqueous surfactant solution containing 2.5 mg/mL polyvinyl alcohol (PVA) (Sigma-Aldrich Cat. No. 363138) and 2.5 mg/mL avidin-palmitate bioconjugate (previously described 15 ), and sonicated to create an emulsion containing nanosized droplets of polymer/solvent, encapsulated cytokine and surfactant. Solvent was removed by magnetic stirring at room temperature; hardened nanoparticles were then washed 3× in DI water and lyophilized for long-term storage. CD4-targeted nanoparticles were formed by reacting avidincoated NPs in PBS with 4 µL of biotin-anti-CD4 (0.5 mg/ mL) per mg NP for 15 min and used immediately. Nanoparticle size and morphology were analyzed via scanning electron microscopy and dynamic light scattering in 1× PBS (Brookhaven Instruments, ZetaPALS). Cytokine release was measured by incubating particles in PBS at 37°C and measuring cytokine concentrations in supernatant fractions by ELISA. Total encapsulation was approximated as the amount of LIF or IL-6 released over a seven day period and percent encapsulation efficiency calculated as total encapsulation divided by maximum theoretical encapsulation. Capture of biotinylated ligands was quantified using biotin-R-phycoerythrin as a model protein. NPs were suspended at 1.0 mg/mL in 1× PBS, and 200 µL was added to eppendorfs containing varying concentrations of biotin-R-PE. NPs were reacted for 15-30 min at room temperature and centrifuged for 10 min at 12 000 RPM, and the remaining biotin-R-PE in the supernatant was quantified by fluorescence at excitation/emission 533/575 nm. All data are presented as mean ( standard deviation.
Animals. Foxp3-GFP knockin mice were generated on a C57BL/6 background as previously described, 16 then backcrossed for 8 generations onto the BALB/C background. DBA/2 mice were purchased from Jackson Laboratory. BALB/c and CBA mice were purchased from Harlan for use at 10-12 weeks of age.
In Vitro T Cell Stimulation. As previously described 7 FACS-sorted CD4+GFP-mouse naive cells were stimulated in flat bottomed 96-well plates with plate-bound anti-CD3 (10 µg/mL), soluble anti-CD28 (1 µg/mL), and IL-2 (50 ng/ mL). For Foxp3+ Treg induction, cultures were supplemented with TGF-(5 ng/mL). For Th17 induction, cultures were supplemented with TGF-and IL-6 (20 ng/mL). All concentrations account for total well volume after addition of control media or nanoparticle-containing media. Cells were imaged by SEM and fluorescent microscopy after incubation with or without CD4-targeted NPs. For SEM, naive CD4+ T cells were stimulated for 24 h with or without CD4-targeted LIF-nano. Cells were collected by centrifugation (3000 rpm), fixed in 4% paraformaldehyde + 0.1% glutaraldehyde for 15 min and then in 4% paraformaldehyde for an additional 45 min before being washed twice in 1× PBS. For fluorescent experiments, naive CD4+ T cells were incubated with or without CD4-targeted nanoparticles containing coumarin-6 for 2 h at either 37°or 4°C. Cells were 
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For the non-human primate (NHP) MLR experiments, blood samples from mismatched Rhesus monkeys were obtained from the Biomedical Primate Research Centre, Rijswijk, The Netherlands. Using peripheral blood mononuclear cells, the MLR general procedure followed that described by Haandstra et al. 17 The current experiments employed one way MLR cultures comixed in bulk and then aliquoted in triplicate into round-bottomed microtiter wells containing either (i) LIF-nanoparticles targeted to CD4 (biotin-antihuman CD4 from eBioscience Cat. No. 13-0049); (ii) empty nanoparticles targeted to CD4; (iii) soluble recombinant human LIF (10 ng/mL); (iv) soluble recombinant human IL6 (10 ng/mL); (v) soluble LIF plus anti-hIL6 (R&D AB-206-NA); (vi) soluble IL6 plus anti-hLIF; or (vii) no additions (control). All treatment stocks were freshly prepared. Replicate plates were analyzed by flow cytometry for CD4, CD25 and FOXP3 (eBioscience human/NHP Treg staining kit) at 7 days and at 11 days: for the 11 day cultures, the cultures were reboosted at 7 days with fresh irradiated donor peripheral blood mononuclear cells (pbmc). In addition to percent distribution counts, actual numbers of FOXP3 positive cells per well were calculated.
In ViWo Donor-Specific Transfusion (DST). As previously described 7 DBA/2 splenocytes were treated for 15 min with CD4-targeted unloaded (empty), LIF-loaded, or IL-6-loaded nanoparticles. The NP-bound cells (10 7 per mouse) were infused iv into BALB/c Foxp3-GFP mice (n ) 3 per group). Lymph nodes were harvested after 5 days, and the ratio of GFP+ (Treg) to GFP-CD4+ cells was calculated in donor-specific V 6 or nonspecific V 8. Data are reported as mean ( standard deviation.
Mismatched Murine Heart Allograft Transplant Rejection. Vascularized mouse heart allografts from BALB/c donors to the neck of CBA recipients followed previously published procedures.
18 BALB/c to CBA is a full mismatch combination that results in graft rejection at ∼7 days in untreated controls, as determined by cessation of grafted heart beat. At 0 day, experimental groups received either (i) nothing; (ii) CD4-targeted empty nanoparticles; (iii) a donorspecific blood transfusion (DST) ip administration of 2 × 10 7 BALB/c spleen cells; or (iv) DST premixed with CD4-targeted LIF-nanoparticles. All treatments were ip and as a single dose on day of transplant.
Results
CD4-Targeted PLGA Nanoparticles Deliver Bioactive LIF and IL-6. Avidin-coated PLGA nanoparticles were observed by scanning electron microscopy to be discrete and spherical (Figure 2A ). Nanoparticle diameters were calculated to be 100 ( 20 nm (mean ( SD) by Scion Image software ( Figure 2B ). Nanoparticle hydrodynamic diameter was analyzed by dynamic light scattering in 1× PBS. The effect of ligand coating was assessed by adding 0.1× or 10× molar excess of biotinylated anti-CD4 in serial fashion to LIF-nano. Biotinylated ligands were attached to the nanoparticles immediately prior to use as described in the Experimental Section and in previous publications.
12,13 Addition of bioti- nylated anti-CD4 was not found to have a significant effect on the mean effective diameter of nanoparticles in PBS ( Figure 2C ). Data are reported as mean ( SD of 10 readings with polydispersity index reported in parentheses above columns. Ligand attachment was quantified using biotin-R-PE as a model protein. LIF-nano were incubated with biotin-R-PE in increasing molar concentrations. Surface-coated nanoparticles were then removed by centrifugation and the remaining fraction of biotin-R-PE in the supernatant measured by fluorescence. LIF-nano were found to stably bind up to 6.2 ( 2.3 µg (1.6 ( 0.6 × 10 13 molecules) of biotin-R-PE (mean ( SD of all data points) ( Figure 2D ). The number of NPs was measured to be between 5 × 10 10 and 1 × 10 11 NPs per mg by a Nanosight particle tracking instrument. The approximate number of ligands per nanoparticle was therefore calculated by dividing the molecules of biotin-R-PE attached by the number of nanoparticles, leading to an estimate of 100-400 ligands per nanoparticle. Release of IL-6 or LIF from nanoparticles was assessed by incubating samples in triplicate in PBS at 37°C and measuring cytokine release into the supernatant by ELISA. The cumulative release was measured to be 1000 ( 50 pg of LIF/mg of LIF-nano ( Figure 2E ) and 2400 ( 360 pg of IL-6/mg of IL-6-nano over a 7 day period ( Figure 2F ). Release beyond 7 days was not significant. The data represent mean ( SD for 3 or more separate samples.
The LIF/IL-6 Axis Can Be Modulated in Vitro Using Nanotherapy. Activation of naive CD4+ T cells in the presence of transforming growth factor beta (TGF-) alone is known to induce Foxp3 expression while, in contrast, activation in the presence of both IL-6 and TGF-results in RORγT expression. 16 We therefore examined the bioactivity of nanoparticle-delivered LIF or IL-6 and their effect on differentiation of naive CD4+ T cells in Vitro through the expression of these lineage-specific transcription factors. LIF was found to augment the expression of Foxp3. Naive CD4+ T cells were activated with anti-CD3, anti-CD28, and IL-2 in the presence of 1 ng/mL TGF-and increasing doses of LIF or LIF-nano. Higher doses of LIF supported development of Foxp3 expression, but interestingly a 0.1 mg/mL dose of LIF-nano was as effective as a 10-100 ng/mL dose of soluble LIF ( Figure 3A) , suggesting an approximate 1000-fold increase in potency when adjusting for relative dose by the total 7-day release of LIF from Figure 2E . This phenomenon was also observed in IL-6-mediated suppression of Foxp3 expression. We found that IL-6-nano were more effective at suppression of Foxp3 than equivalent doses of soluble IL-6 at doses between 1 and 100 pg/mL ( Figure 3B) . The maximum dose of NPs given was 0.2 mg/mL, due to cytotoxic effects at higher concentrations ( Figure 3C ). However, nanoparticle cytotoxicity was not determined to be a factor at the doses used. PLGA NPs incubated with T cells under standard stimulation conditions did not have cytotoxic effects against CD4+ T cells at concentrations below 0.1 mg/mL ( Figure 3C ). Representative FACS plots of the comparative effects of IL-6 and LIF on Foxp3 expression are shown in Figure 3D .
LIF-nano and IL-6 nano were found to have counteracting effects on RORγT expression. Naive CD4+ T cells were activated with anti-CD3, anti-CD28, and IL-2 in the presence of 1 ng/mL TGF-and increasing doses of IL-6 or IL-6-nano. IL-6-nano were found to induce RORγT expression in greater than 70% of the population at significantly lower doses than soluble IL-6 ( Figure 4A ). The minimum effective dose of soluble IL-6 used (1 ng/mL) was found to only induce approximately 40% RORγT expression. Conversely, LIF-nano were found to suppress RORγT expression. In these experiments, naive CD4+ T cells were activated in media containing 1 ng/mL TGF-, a high dose (20 ng/mL) of soluble IL-6, and increasing doses of LIF-nano or LIF soluble. Assuming full potential release of 1000 pg of LIF/ mg of NP, nanoparticle-delivered cytokine was observed to be approximately 1000-fold more potent than soluble LIF in suppression of RORγT ( Figure 4B ). We note that LIF therapy at higher doses of either soluble or nanoparticleloaded cytokine did not demonstrate significant toxic or proliferative effects on CD4+ T cells ( Figure 4C ). Representative FACS plots of highest cytokine or nanoparticle doses are shown to highlight the counter-regulatory effect of IL-6 and LIF on RORγT expression ( Figure 4D ).
The interaction between T cells and nanoparticles was observed using SEM as well as fluorescent microscopy. Under SEM, CD4+ T cells were found to be approximately 5 µm in diameter with a relatively smooth surface after 24 h of stimulation ( Figure 5A ). When CD4-targeted LIF-nano was added to the stimulation media, distinct nanoparticles could be observed on the lymphocyte surface even after cells were washed ( Figure 5B ). Nanoparticles encapsulating the fluorescent dye coumarin 6 (C6-nano) were used to further visualize T-cell-nanoparticle interactions. CD4+ T cells were incubated with C6-nano at 37 or 4°C for 2 h, then washed, fixed, and stained with Texas-Red-phalloidin and DAPI. CD4+ T cells were observed to have large nuclei and intact membrane ( Figure 5C ). After the addition of CD4-targeted C6-nano, nanoparticles were found associated with the cell surface regardless of temperature ( Figure 5D,E) . Thus the observed increase in bioactivity may be due to stable and enhanced interaction of targeted nanoparticles with CD4+ T cells. Unlike our previous report demonstrating significant internalization of PLGA particles by phagocytic dendritic cells, 19 we did not observe significant nanoparticle fluorescence within the lymphocyte cytosol. The exact mechanism of enhanced bioactivity remains an area of ongoing investigation, but we note that this observation is consistent with our previous report demonstrating increased bioactivity of IL-2 when delivered from PLGA particles.
13
LIF-Nano Are Tolerogenic in ViWo in the Mouse. We had previously demonstrated that that CD4-targeted LIF-nano bias the in ViVo immune response toward tolerance, as measured by the relative numbers of antigen-specific Foxp3+CD4+ T cells following donor-specific transfusion (DST). 7 We repeated these experiments using IL-6-nano to treat lymphocytes prior to DST. Pretreatment of naive donor CD4+ T cells with CD4-targeted LIF-nano resulted in a nearly 4-fold increase in the ratio of antigen-specific (e.g., v 6+, solid black bars) GFP+Foxp3+/GFP-Foxp3-cells ( Figure 6A) . A slight increase in the Treg ratio was observed with the empty-nano control. This effect is likely due to the presence of anti-CD4 antibodies on the particle surface and is consistent with previous reports demonstrating that anti-CD4 blockade supports foxp3 induction. 20, 21 Notably, the effect was abrogated completely when donor cells were pretreated with CD4-targeted IL-6-nano ( Figure 6A ). We therefore conclude that the expansion of antigen-specific Foxp3+ cells is indeed due to the bioactivity of LIF-nano. We then examined whether LIF-nano could be utilized for therapeutic effect in support of a functioning allograft in ViVo.
We used a difficult but highly reproducible mouse model of vascularized heart allografts between fully mismatched donor-recipient mice (BALB/c to CBA). Following allograft transplantation, animals received donor-specific transfusions in similar fashion to the study in ( Figure 5A ). Animals receiving no supporting treatment or DST alone suffered graft rejection 7 days after implantation ( Figure 6B ). Combination therapy (DST in concert with a single dose of CD4-targeted LIF-nano) at the time of grafting significantly increased mean survival time from 7 days to 12 days (n ) 3 or more animals, p < 0.01 by Pearson's chi-square analysis). Although analysis of tissue-infiltrating lymphocytes was not conducted due to the end point nature of the studies, we note that the increased survival in the DST + LIF treatment group appears to correlate with the group in which the greatest expansion of Tregs in healthy recipient mice was observed ( Figure 6A ).
LIF-Nano Are Tolerogenic in Vitro in the Rhesus
Monkey. The Rhesus monkey mixed lymphocyte reaction (MLR) was used as a preclinical model to test the efficacy of LIF nanotherapy. Primary MLRs were measured at 7 days, and persistence of therapeutically induced effects was measured at 11 days after rechallenge with donor antigen on the seventh day. Treatment with CD4-targeted LIF-nano resulted in a 4-fold increase in percentage of CD4+ CD25+FOXP3+ T cells in cultures at 11 days, while emptynano or soluble LIF had little effect ( Figure 7A) . Analysis of the total numbers of cells per culture showed expansion of CD4+ T cells in the CD4-targeted LIF-nano treatment group relative to all other groups ( Figure 7B ). Within this expanded CD4+ T cell population, there was greater than 10-fold increase in CD4+CD25+FOXP3+ cells relative to untreated control ( Figure 7B ).
It was important to establish that any measured effects were due to the delivery of LIF, rather than being a consequence of nonspecific CD4+ T cell activation due to cross-linking of the CD4 coreceptor by the delivery vehicle itself. This was clearly demonstrated as empty, CD4-targeted nanoparticles failed to induce Foxp3+ cells ( Figure 7B ). Second, it was important to show that nanoparticle-mediated delivery of LIF was required; this was demonstrated since soluble LIF alone failed to recapitulate the induction of Foxp3+ cells, with only 2-fold increase in CD4+ cell numbers and Foxp3+ expression ( Figure 7B ). These studies demonstrate that non-human primate cells also respond to LIF-nano and that here too the LIF-nano induce expansion of CD4+CD25+FOXP3+ T cells in response to donor antigen; importantly these effects were sustained following further antigenic challenge.
Discussion
Overall, our findings strongly support the notion that endogenous control mechanisms that regulate immune tolerance can be exploited using nanotherapeutic devices to both deliver and release regulatory cytokines in a stable, physiological manner. We have focused our study on LIF, following our previous discovery that LIF is a tolerogenic cytokine able to counter-regulate IL-6. We demonstrate that LIF and IL-6, both members of the IL-6 cytokine family, can be stably encapsulated and released in bioactive form using PLGA nanoparticles. The effect of nanoparticledelivered cytokine was shown to be highly specific; nanoparticle-delivered LIF was found to enhance Foxp3+ and repress RORγT expression, while nanoparticle-delivered IL-6 induced the opposite effects. This specificity of action is consistent with previous understanding regarding the bioactivity 5,16 of the cytokines and further confirms the critical regulatory axis in T cells that is counter-regulated by LIF and IL-6. 7 We note that these effects are likely due to their respective receptors, where IL-6 is composed of gp130 homodimers, and LIF of gp130/gp190 heterodimers.
5
Since gp190 is the critical determinant in LIF signaling (and thus in the LIF/IL6 axis), it is highly relevant to note that axotrophin, an RINGv E3-ligase linked to regulatory transplantation tolerance, 6 plays a role in degradation of gp190 and has profound regulatory effects on T lymphocytes including their release of endogenous LIF.
7,22
Recent progress in the understanding of the plasticity of T cell fate gives broader significance to these findings. T cell fate between Treg versus Teff may be determined by progressive epigenetic programming that follows activation of the naive T cell, with lineage commitment becoming progressively more stable and less vulnerable to the immediate microenvironment over time. 3, 23, 24 It therefore follows that sustained delivery of LIF will in turn sustain the LIF-feed-forward loop toward hard-wiring of the Treg epigenetic profile, including the stable expression of Foxp3. Targeting of LIF-encapsulating nanoparticles to CD4+ T cells enables this specific, sustained delivery of LIF in the face of dynamic physiologic factors such as diffusion and clearance. In the mouse DST and heart allograft studies, an increase in antigen-specific, Foxp3+ Tregs was only observed when lymphocytes were treated with CD4-targeted LIF-nano; highly localized nanoscale sources of cytokine may 
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VOL. xxx, NO. xx MOLECULAR PHARMACEUTICS I represent a significant benefit over any dose of soluble therapeutic. We believe that LIF-nanodriven immune tolerogenesis heralds a novel, antigen specific approach to immunemediated disease. Moreover, since LIF is also an important factor for supporting stem cells, the use of LIF-nano in regenerative medicine provides 2-fold benefit, supporting engrafted stem cells in addition to protecting them from immune-mediated rejection.
